New Drug Combo Delayed Disease Progression for Subgroup of Women With Metastatic Breast Cancer

Article
Conference|San Antonio Breast Cancer Symposium (SABCS)

Adding dasatinib to standard antihormone therapy letrozole significantly improved the progression-free survival of women with hormone receptor–positive, HER2-negative metastatic breast cancer, according to the results of a small phase II study. Investigator Dev Paul, DO, PhD, of Rocky Mountain Cancer Centers cautioned that more information is needed to determine which patients will benefit from the addition of dasatinib.

Recent Videos
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Mets
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
Perioperative Durvalumab Yields Improved Efficacy in NIAGARA Regimen
Perioperative Durvalumab Yields Improved Efficacy in NIAGARA Regimen
The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
Durvalumab/Chemotherapy Deserving of Consideration in Neoadjuvant MIBC
Durvalumab/Chemotherapy Deserving of Consideration in Neoadjuvant MIBC
Related Content
Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Tim Cortese
April 3rd 2025
Article

Most patients with cancer who took part in a telehealth group expressed that they liked the members of their group and felt less social isolation.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

Ariana Pelosci
April 1st 2025
Article

An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.

PIPAC-MMC Plus FOLFIRI Shows Feasibility, Safety in Peritoneal Metastases

Roman Fabbricatore
March 31st 2025
Article

Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

Tim Cortese
March 31st 2025
Article

A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.